Crescita Therapeutics Inc. announced that it has signed an exclusive distribution agreement (the ?Agreement?) with NanoPass Technologies Ltd. (?NanoPass?), a pioneer in the development and commercialization of an advanced intradermal delivery device, to launch and distribute MicronJetTM600 (?MicronJet?) in the Canadian medical aesthetics market. MicronJet is an innovative intradermal injection device, leveraging the proven MEMS technology, that offers a highly effective, consistent and virtually pain-free delivery of aesthetic products and therapeutic substances. With three 0.6mm, silicon crystal-made delivery pyramids, MicronJet can be attached to standard syringes and will provide aesthetic clinicians with the least invasive and most precise intradermal delivery on the market today, allowing administration to delicate and sensitive areas such as around the eyes, neck and décolleté area, as well as to the full face, for optimal patient outcomes.

Crescita will be responsible for obtaining regulatory approval for MicronJet from Health Canada and plans to launch the product promptly thereafter, which is currently anticipated to be in the first half of 2025. MicronJet has been accepted by patients worldwide and is supported by over 70 clinical studies and multiple peer reviewed publications. MicronJet is CE marked, U.S. FDA cleared, ISO 13485 certified and is currently approved in Australia and several other jurisdictions in Europe, Asia and the Middle East.